Cervical Cancer Involves Chemotherapy Clinical And Pathological Observations And Efficacy Study

Cervical cancer is the most common malignant tumor in gynecology, worldwide, cervical cancer cases occur each year about 50 million new, while the patients died from cervical cancer each year some 24 million. For a long time, surgery and radiotherapy is the main treatment for cervical cancer. Mainly used in surgical treatment of cervical cancer to otherⅠA-ⅡA in between patients. And radiotherapy for cervical cancer mainlyⅡB of the other is the late stageⅢor above, or inoperable patients. Large lesions on the local advanced cervical cancer patients treated with surgery combined with radiotherapy, the eradication of residual lesions and local transfer and reduce the probability of recurrence of cervical cancer.In recent years, foreign scholars to promote chemotherapy combined with surgery or radiotherapy, to improve the resection rate of cervical cancer and radiation sensitivity. Proposed for cervical cancer or radiotherapy before surgery can be conducted several courses of chemotherapy. The main target for the treatment of locally advanced cervical cancer patients with poor prognostic factors is a high risk of cervical cancer patients. The intervention for preoperative chemotherapy for cervical cancer treatment, cervical cancer is called neoadjuvant chemotherapy (neoadjuvant chemotherapy, NACT). Specific operating practices is through the femoral artery to internal iliac artery before the dry, or even into the uterine artery can be AMD, and then were perfused with anti-tumor chemotherapy drugs and gelatin sponge particles as embolic agents based on cancer chemotherapy, embolization of tumor feeding arteries.Materials and methods:1. This study of the cases were selected from December 2004-2010 period in July, the Court admitted for treatment of gynecological and clinical staging criteria identified asⅠB2-ⅢA stage, all untreated cases of primary cervical cancer patients. Preoperative treatment with neoadjuvant chemotherapy as initial treatment, follow-up to surgical treatment, complete clinical data of 54 cases of primary cervical cancer as NACT observation group. Select the same period in the hospital for treatment of gynecological cancer patients with surgery for the initial treatment, and improve the clinical pathological data of 50 patients with primary cervical cancer as a surgical control group.2.Study, the use of cisplatin and epirubicin internal iliac arterial infusion chemotherapy, further surgery or radiotherapy, chemotherapy, curative effect observation of intervention, toxicity, effects of surgery and chemotherapy before and after the intervention of tumors and other pathological changes.3.The data are used SPSS 10.0 statistical softwareχ2 test to P<0.05 was considered statistically significant.Results:1.The results show that chemotherapy after 1～3 courses of intervention, the total effective rate was 94.4%, pathological examinations showed massive necrosis of tumor cells and degenerative, with no severe toxicity.2.NACT in 51 cases of the observation group won the chance of operation, intraoperative cervical lesions organizations see the narrow, loose tumor easily separated, reduced operative time and blood loss, operative difficulty reduced.3.5 years survival rate of 93.3%, relapse rate and mortality. In particular, NACT observation group, the age of 45 years of age patients retained ovarian function and integrity of the vagina function. Conclusion:1.The results showed that epirubicin cisplatin preoperative interventional chemotherapy for cervical cancer can be significantly reduced lesions, surgery to improve compliance, so advanced or bulky tumor in young patients the opportunity to receive surgical removal of lesions.2.Its recent good efficacy, toxic side effects, recurrence rate, higher survival rate after surgery, it is worth further clinical research applications.3.Cervical cancer despite preoperative intervention effective, but can not completely eliminate the tumor, or inhibition of tumor growth, and the role of chemotherapy limited time, we must grasp the favorable opportunity of the follow-up surgery.4.Meanwhile, according to the patient's general status and tumor size, clinical stage, development of individualized treatment plan is necessary.